Patient Care Editorial Staff

Merilog joins two long-acting insulin biosimilar products approved in 2021, bringing the total to three insulin biosimilars available in the United States.

The development comes at a time when cannabis use disorder has risen steadily in the United States.

The Winter Clinical Hawaii Dermatology Conference will kick off on the Big Island on February 14th. Check out the agenda and the option to attend virtually.

The FDA set a PDUFA action date of December 12, 2025 for lerodalcibep, according to LIB Therapeutics.

The FDA has set the Prescription Drug User Fee Act target action date for bronchiectasis for August 12, 2025, Insmed Incorporated announced.

Vesper Bio anticipates completing enrollment and dosing by mid-2025 in the Phase 1B/2A trial for VES001.

These test panels allow clinicians to diagnose multiple STIs from a single specimen, with results available in about 20 minutes.

Cebranopadol, an investigational oral dual-NMR agonist, satisfied the primary endpoint of statistically significant reduction in pain intensity compared to placebo following abdominoplasty surgery.

The approval of esketamine follows an FDA Priority Review and is based on data showing that esketamine alone demonstrated rapid and superior improvement in depressive symptoms compared with placebo.

Findings of the study support the AHS 2024 statement supporting CGRP inhibitors as first-line options and calling for reducing overall costs of migraine treatment.

An earlier phase 2 study found statistically significant improvement of MDD in female participants.

The adcomm meeting is expected to happen in the first half of 2025, and means the FDA expects to miss the target PDUFA date.

Buntanetap is an oral molecule designed to inhibit the production of multiple neurotoxic proteins and is under investigation for treatment of Alzheimer Disease, Parkinson’s Disease, and other neurodegenerative diseases.

This marks the second indication for tirzepatide in just more than a year, following its November 2023 approval for adults with obesity or overweight and weight-related medical problems.

Oral sulopenem is the first oral penem approved in the US for treating uUTIs in women with limited options.

Boehringer Ingelheim announces plans to submit NDA for Investigational Therapy.

ACC 2022. ACC late-breaking clinical trial sessions begin Sat, April 2, 2022. Our short slide shows highlight the studies of interest to primary care clinicians.

At ACC 2022 on Sunday, 4-2, look for studies on icosapent ethyl and alirocumab, landmark research on HFrEF, and a novel anticoagulant for atrial fibrillation.

At ACC 2022 on Sunday, 4-2, look for studies on icosapent ethyl and alirocumab, landmark research on HFrEF, and a novel anticoagulant for atrial fibrillation.

AAAAI late-breaking science and findings that could change your treatment plan for patients with severe asthma, summarized by our editors for easy access.

ADA 2021 Scientific Sessions recap, tests of clinical knowledge, expert interviews, and more in this roundup from Patient Care Online.

The MJH Life Sciences COVID-19 Coalition is a partnership with 10 nationally recognized experts. They comment on the issues driving the US response to the pandemic.

In episode 5 of Primary Viewpoints, Jonathan Chow, MD, reviews the landmark study findings that patients with COVID-19 taking low-dose aspirin had reduced risk for death.

Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.

Nearly two-thirds of physicians say the COVID-19 pandemic has made them feel more burned out.

Refresh your memory of the short yet crowded history of the COVID-19 pandemic with our 8-question quiz.

Physicians shared what ancillary services they provided most often in 2019 and how they earned secondary income, in the Medical Economics 91st annual Physician Report.

Physicians break down how much they earn across a variety of criteria, including practice ownership, gender, age, community type, and more.

Five cases of the 2019 novel coronavirus have been confirmed in the US. The CDC provides this guide to help front-line providers prepare.

The novel test was shown to be effective in the early detection of symptom-free patients with coronary artery disease.